References
- Carvalho AF, Firth J, Vieta E. Bipolar disorder. N Engl J Med. 2020;383(1):58–66.
- Merikangas KR, Jin R, He JP, et al. Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative. Arch Gen Psychiatry. 2011;68(3):241–251.
- Forte A, Baldessarini RJ, Tondo L, et al. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders. J Affect Disord. 2015;178:71–78.
- GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet Psychiatry. 2022;9(2):137–150.
- Yatham LN, Kennedy SH, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord. 2018;20(2):97–170.
- Miller S, Dell'Osso B, Ketter TA. The prevalence and burden of bipolar depression. J Affect Disord. 2014;169(Suppl 1):S3–S11.
- Morton E, Murray G, Michalak EE, et al. Quality of life in bipolar disorder: towards a dynamic understanding. Psychol Med. 2018;48(7):1111–1118.
- Intra-Cellular Therapies announces U.S. FDA approval of CAPLYTA® (lumateperone) for the treatment of bipolar depression in adults. New York: Globe Newswire; December 20; 2021. Available from: https://ir.intracellulartherapies.com/news-releases/news-release-details/intra-cellular-therapies-announces-us-fda-approval-caplytar.
- Rajagopalan K, Bacci ED, Ng-Mak D, et al. Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials. BMC Psychiatry. 2016;16:157.
- Calabrese JR, Durgam S, Satlin A, et al. Efficacy and safety of lumateperone for major depressive episodes associated with bipolar I or bipolar II disorder: a phase 3 randomized placebo-controlled trial. AJP. 2021;178(12):1098–1106.
- Endicott J, Rajagopalan K, Minkwitz M, et al. A randomized, double-blind, placebo-controlled study of quetiapine in the treatment of bipolar I and II depression: improvements in quality of life. Int Clin Psychopharmacol. 2007;22(1):29–37.
- Ketter TA, Sarma K, Silva R, et al. Lurasidone in the long-term treatment of patients with bipolar disorder: a 24-week open-label extension study. Depress Anxiety. 2016;33(5):424–434.
- Loebel A, Cucchiaro J, Silva R, et al. Lurasidone monotherapy in the treatment of bipolar I depression: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2014;171(2):160–168.
- Endicott J, Nee J, Harrison W, et al. Quality of life enjoyment and satisfaction questionnaire: a new measure. Psychopharmacol Bull. 1993;29(2):321–326.
- Cohen J. Statistical power analysis for the behavioral sciences. New York, NY: Routledge Academic; 1988.
- Endicott J, Paulsson B, Gustafsson U, et al. Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord. 2008;111(2–3):306–319.
- Calabrese J, Rajagopalan K, Ng-Mak D, et al. Effect of lurasidone on meaningful change in health-related quality of life in patients with bipolar depression. Int Clin Psychopharmacol. 2016;31(3):147–154.
- Rush AJ, South C, Jain S, et al. Clinically significant changes in the 17- and 6-item Hamilton rating scales for depression: a STAR*D report. Neuropsychiatr Dis Treat. 2021;17:2333–2345.
- Niu X, Dembek C, Fan Q, et al. The impact of lurasidone on functioning and indirect costs in adults with bipolar depression: a post-hoc analysis. J Med Econ. 2022;25(1):152–159.
- Léda-Rêgo G, Bezerra-Filho S, Miranda-Scippa Â. Functioning in euthymic patients with bipolar disorder: a systematic review and meta-analysis using the functioning assessment short test. Bipolar Disord. 2020;22(6):569–581.